Biocon Biologics Switzerland AG
BALANCE SHEET AS AT MARCH 31, 2026
(All amounts in CHF Thousands, except share data and unless otherwise stated)

	Notes	March 31, 2026	March 31, 2025
ASSETS			
Non-current assets			
Income-tax asset (net)		2	-
Deferred tax asset (net)		30	-
Total non-current assets		**32**	**-**
Current assets			
Inventories	1	1,402	1,087
Financial assets			
(i) Trade receivables	2	1,363	268
(ii) Cash and cash equivalents	3	1,133	180
Other current assets	4	-	1
Total current assets		**3,898**	**1,536**
TOTAL		**3,930**	**1,536**
EQUITY AND LIABILITIES			
Equity			
Equity share capital	5	50	50
Other equity	6	151	67
Total equity		**201**	**117**
Current liabilities			
Financial liabilities			
(i) Trade payables	7	3,266	1,156
(ii) Other financial liabilities			
Income-tax liability (net)		67	16
Provisions	8	52	47
Other current liabilities	9	344	200
Total current liabilities		**3,729**	**1,419**
TOTAL		**3,930**	**1,536**

Biocon Biologics Switzerland AG
STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2026
(All amounts in CHF Thousands, except share data and unless otherwise stated)

	Notes	Year ended March 31, 2026	Year ended March 31, 2025
Income			
Revenue from operations	10	3,370	1,734
Other operating income	11	8	245
Total revenue		**3,378**	**1,979**
Expenses			
Purchases of traded goods	12	275	(223)
Changes in inventories of traded goods	13	(315)	(166)
Employee benefits expense	14	2,565	1,747
Other expenses	15	716	550
Total expenses		**3,241**	**1,908**
Profit/(loss) before exceptional item and tax		**137**	**71**
Exceptional items		(32)	-
Profit/(loss) before tax		**105**	**71**
Tax expense			
Current tax		51	(23)
Deferred Tax		(30)	37
Total tax expense		**21**	**14**
Profit for the year		**84**	**57**

Biocon Biologics Switzerland AG
STATEMENT OF CASH FLOWS FOR THE YEAR ENDED MARCH 31, 2026
(All amounts in CHF Thousands, except share data and unless otherwise stated)

		Year ended March 31, 2026	Year ended 'March 31, 2025
I	**Cash flows from operating activities**		
	Profit after tax	**84**	**57**
	Adjustments to reconcile profit before tax to net cash flows:		
	Tax expense	21	14
	Operating profit before working capital changes	**105**	**71**
	Movements in working capital		
	(Increase) in trade receivables	(1,095)	(5)
	(Increase) in trade inventories	(315)	(166)
	(Increase) in loans and advances and other assets	1	(1)
	Increase/ (Decrease) in trade payable, other liabilities and provisions	2,257	(160)
	Cash generated from/(used in) operations	**953**	**(261)**
	Direct taxes paid	-	-
	Net cash flow (used in) /generated from operating activities	**953**	**(261)**
II	**Net increase/(decrease) in cash and cash equivalents (I)**	**953**	**(261)**
III	Cash and cash equivalents at the beginning of the year	180	441
IV	**Cash and cash equivalents at the end of the period (II +III)**	**1,133**	**180**
	Reconciliation of cash and cash equivalents as per statement of cash flow		
	Cash and cash equivalents		
	Balances with banks - on current accounts	1,133	180
		1,133	**180**
	Total cash and cash equivalents [Refer note 3]	**1,133**	**180**

Biocon Biologics Switzerland AG
Notes to financial statements for the year ended March 31, 2026
(All amounts in CHF Thousands, except share data and unless otherwise stated)

	March 31, 2026	March 31, 2025
1. Inventories		
Finished Goods	1,402	1,087
	1,402	**1,087**
2. Trade receivables		
Other Receivables		
Outstanding for a period less than six months from the date they are due for payment		
Unsecured, considered good	1,363	268
	1,363	**268**
3. Cash and cash equivalents		
Balances with banks:		
On current accounts	1,133	180
	1,133	**180**
4. Other current assets		
Prepayments	-	1
	-	**1**
5. Share capital		
100,000 Equity share of CHF 0.5 each	50	50
	50	**50**
6. Other equity		
Surplus in the statement of profit and loss		
Balance as per the last financial statements	67	10
Profit for the year	84	57
Net surplus in the statement of profit and loss	**151**	**67**
Total other equity	**151**	**67**
7. Trade payables	**3,266**	**1,156**
8. Provisions		
Current		
Compensated absences	52	47
	52	**47**
9. Other liabilities		
Current liabilities		
Statutory liabilities	344	200
	344	**200**

Biocon Biologics Switzerland AG
Notes to financial statements for the year ended March 31, 2026
(All amounts in CHF Thousands, except share data and unless otherwise stated)

	Year ended March 31, 2026	Year ended March 31, 2025
10. Revenue from operations		
Sale of Products		
Traded Goods	2,764	1,498
Sale of Services		
Support service cross charge to Group Companies	606	236
	3,370	**1,734**
11. Other operating income		
Foreign exchange fluctuations, net	8	(9)
Support service cross charge to Group Companies	-	254
	8	**245**
12. Purchase of traded goods	275	(223)
	275	**(223)**
13. Changes in inventories of traded goods		
Inventory at the beginning of the year		
Traded goods	1,087	921
Inventory at the end of the year		
Traded goods	1,402	1,087
	(315)	**(166)**
14. Employee benefits expense		
Salaries, wages and bonus	2,378	1,479
Contribution to Defined Cont'n Plan	65	148
Employee stock compensation expense	122	120
	2,565	**1,747**
15. Other expenses		
Rates and taxes	72	-
Rent	2	5
Legal and professional fees	175	261
Travelling and conveyance	126	64
Selling expenses		
Sales promotion expenses	43	56
Distribution Expenses	145	98
Printing and stationery	11	14
Communication expenses	5	4
Miscellaneous expenses	135	46
Insurance Charges	2	2
	716	**550**